TY - JOUR T1 - Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal JO - PharmacoEconomics UR - http://eprints.whiterose.ac.uk/137968/ PY - 2018/09/24 AU - Tappenden P AU - Simpson E AU - Hamilton J AU - Pollard D AU - Clowes M AU - Kaltenthaler E AU - Meiklejohn D AU - Morley N ED - DO - DOI: 10.1007/s40273-018-0713-7 Y2 - 2025/05/31 ER -